Theradiag announces sales of 6.69 million euros to end June 2023, up 6.8% year-on-year, including a 7.4% increase to 3.38 million in the second quarter alone.

Growth accelerated slightly in the second quarter of 2023, thanks to good sales performances in both Theradiag business lines (+9.4% for theranostics and +5.3% for in vitro diagnostics).

"On the strength of a comfortable cash position, we intend to pursue the development and accelerate the marketing of our high-margin, in-house-manufactured products over the coming months", says CEO Simon Davière.

Copyright (c) 2023 CercleFinance.com. All rights reserved.